DDInter814 DDInter1676
Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody [FDA Label]. The antibody is specifically directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML). By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and causes cell death. Marketing approval of gemtuzumab ozogamicin was granted on May 17, 2000 by FDA as a treatment for patients with CD33-positive AML in first relapse who are 60 years of age or
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Gemtuzumab ozogamicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Moxifloxacin
Gemtuzumab ozogamicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Escherichia coli
Gemtuzumab ozogamicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Gemtuzumab ozogamicin {u} may lead to a major life threatening interaction when taken with {v} Lomitapide
Gemtuzumab ozogamicin {u} may lead to a major life threatening interaction when taken with {v} Etanercept
Gemtuzumab ozogamicin may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin
Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli
Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Gemtuzumab ozogamicin may lead to a major life threatening interaction when taken with Lomitapide
Gemtuzumab ozogamicin may lead to a major life threatening interaction when taken with Etanercept